ArticleJournal of ovarian research2026
Identification of ovarian cancer-associated antigens forming complexes with autoantibodies.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTumor-associated antigen (Ag)-autoantibody (AAb) complexes are known to be present in the circulation of patients with multiple types of cancer; however, their significance remains poorly understood.
methodsWe performed immunoblotting of whole cell extracts of the human ovarian cancer cell lines AMOC2, OVCAR3 and SKOV3 with either free antibodies (Abs) or antigen-dissociated Abs obtained from ovarian cancer ascites and healthy sera. In addition, Ag-AAb complexes isolated from ovarian cancer ascites were analyzed by mass spectrometry to identify tumor-associated antigens. Enzyme-linked immunosorbent assay (ELISA) was then used to evaluate the presence of one extracellular matrix (ECM) candidate antigen, SPON1, in its free versus complexed form in ascites and sera.
resultsImmunoblotting revealed that tumor-associated AAbs in ovarian cancer ascites predominantly exist in Ag-AAb complexes rather than as free AAbs. Proteomic profiling identified 72 tumor-associated antigens enriched in ovarian cancer ascites compared with healthy and disease control sera; more than half were ECM- or epithelial–mesenchymal transition (EMT)-related proteins. ELISA demonstrated that SPON1 was preferentially detected as Ag-AAb complexes, but not in its free form, in both ascites and sera of ovarian cancer patients.
conclusionWe uncovered that AAbs predominantly form complexes with tumor-associated antigens in ovarian cancer patients. Since the presence of Ag-AAb complexes has been overlooked in many reports, the identification of tumor-associated antigens and AAbs from Ag-AAb complexes would provide novel insights into their relevance to a variety of cancers and other diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.